查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2126376

癌症基因組分析市場－策略分析與預測（2026-2035）

Cancer Genomic Profiling Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 178 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

癌症基因組分析市場預計將從 2026 年的 85.8 億美元成長到 2035 年的 231.4 億美元，複合年成長率為 11.7%。

癌症基因組分析市場正經歷重大變革，其驅動力源於精準腫瘤學模式轉移，以及人們日益認知到全面的分子特徵分析對於個人化癌症治療至關重要。這一市場演變的特點是，次世代定序和多體學方法在識別可靶向突變、指南治療選擇以及監測多種癌症類型的疾病進展方面得到了越來越廣泛的應用。先進定序技術、人工智慧和液態生物檢體平台的融合，使得基因組分析更加快速、全面且日益普及。隨著標靶治療和免疫療法需要基於生物標記的患者篩選，全球醫療系統正在擴展其基因組檢測能力。隨著市場對全面基因組分析、伴隨診斷和生物資訊解決方案的大量投資，癌症基因組分析正逐漸成為現代癌症診療實踐的基石。

市場促進因素

  • 精準腫瘤學的日益普及是癌症基因組分析市場的主要驅動力。精準醫療需要全面的基因組分析，以識別具有治療意義的突變並制定個人化的癌症治療策略。醫療機構正在擴展其基因組檢測項目，以支持標靶治療的選擇並改善患者預後。診斷設備製造商正在開發全面的基因組分析解決方案，以滿足不斷成長的需求。這種需求加劇了對各類癌症進行基因組檢測的必要性，進而導致癌症基因組分析應用的持續成長。次世代定序技術的快速發展，透過提高診斷準確性、處理能力、降低成本和提高可及性，進一步加速了全球臨床檢查室的市場成長。定序化學、自動化和生物資訊學的持續創新正在拓展基因組分析的臨床效用。技術開發商在降低定序成本的同時，也正在提高分析效能。這些進步正在支持臨床環境中更廣泛的應用和更高的檢測量。標靶治療和伴隨診斷的批准範圍擴大，正在加速腫瘤臨床實踐和研究中常規基因組檢測的發展。基於生物標記的療法獲得監管部門批准，持續推動了伴隨診斷的需求。製藥公司正在拓展其標靶治療的研發管線，這些療法需要進行基因組特徵分析以篩選合適的患者。診斷設備製造商正在開發伴隨診斷解決方案，以支持療法的批准和商業化。全球癌症發病率的上升以及基於生物標記的治療方法的日益增多，推動了對全面分子譜分析解決方案的需求。隨著癌症負擔的加重，篩檢、診斷、治療選擇和後續觀察等各環節的診斷檢測需求持續成長。醫療系統正在擴大其基因組檢測能力，以支持個人化治療策略。

市場限制因素

  • 基因測序平台和生物資訊基礎設施的高成本限制了其在小規模醫院和診斷實驗室的應用。先進技術所需的大量資金投入對小規模醫療機構而言構成障礙。在一些新興醫療市場，全面的基因組分析保險覆蓋範圍有限仍然是一大障礙。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。解讀複雜的基因組數據需要專業知識和先進的生物資訊能力，這阻礙了其在臨床環境中的廣泛應用。缺乏訓練有素的人員和生物資訊基礎設施限制了基因組分析的擴充性。各國監管要求的差異正在減緩先進基因組分析技術的商業化和全球普及。

對科技和使用者畫像類型的洞察

  • 技術發展趨勢的特徵是全面基因組分析和整合生物資訊平台的重要性日益凸顯。 NGS（新一代定序）憑藉其高靈敏度和高通量同時分析多種基因組變異的能力，在技術發展趨勢中佔據主導地位。 PCR（聚合酶鍊式反應）仍廣泛用於標靶突變檢測和伴隨診斷。 FISH（螢光原位雜合技術）在染色體畸變分析中繼續發揮關鍵作用。微陣列技術是基因表現分析的基礎。 Sanger定序仍然適用於確證和檢驗。片段分析表明，由於對廣泛分子表徵以指導治療決策的需求不斷成長，全面基因組分析是成長最快的分析類型。標靶基因組panel分析對於聚焦臨床適用基因仍然至關重要。 WES（全外顯子定序）和WGS（全基因組定序）在需要全面基因組資訊的研究和特定臨床應用領域中不斷擴展。組織檢體仍然是全面基因組分析的黃金標準，因為它們提供高品質的DNA並能夠實現完整的腫瘤表徵。由於液態生物檢體技術能夠實現微創基因組檢測、治療監測和復發檢測，血液檢體檢測的需求成長最為迅速。治療方案選擇是重要的臨床應用領域，伴隨診斷和預後評估也正在快速發展。醫院和診斷檢查室是主要的終端使用者群體，癌症中心和學術研究機構也不斷擴展其基因組檢測能力。隨著人工智慧驅動的生物資訊學能夠改善基因組數據的解讀、支持臨床決策並簡化精準腫瘤學的工作流程，人工智慧的整合變得日益重要。

競爭格局與策略展望

  • 競爭格局包括成熟的診斷和生命科學公司，以及基因組檢測、生物資訊學和液態生物檢體領域的專業供應商。羅氏開發全面的分子診斷、伴隨診斷、定序技術和精準腫瘤學解決方案，以支援基因組分析。 Illumina是NGS平台領域的全球領導者，致力於實現全面的癌症基因組分析和精準醫療。賽默飛世爾科技提供定序系統、PCR技術、基因組分析解決方案和腫瘤研究平台。凱傑開發分子診斷、檢體製備技術、PCR檢測和生物資訊解決方案，以支援基因組檢測。安捷倫提供用於腫瘤診斷的基因組分析儀器、分子檢測、自動化技術和生物資訊解決方案。丹納赫提供先進的基因組平台、分子診斷技術、定序解決方案和實驗室自動化系統。 Guardant Health專注於液態生物檢體、全面的基因組分析和精準腫瘤學檢測，用於晚期癌症的管理。 Exact Sciences致力於開發分子癌症診斷、基因組分析技術和精準腫瘤檢測解決方案。 Foundation Medicine則專注於綜合基因組分析、伴隨診斷和精準腫瘤檢測。兩家公司都在透過在NGS平台、液態生物檢體檢測和人工智慧驅動的生物資訊學方面的創新來拓展產品系列。在伴隨診斷開發和精準腫瘤解決方案的需求驅動下，診斷試劑製造商、製藥公司和研究機構之間的策略合作日益增加。近期的一些重要進展包括：Illumina增強了其在腫瘤領域的綜合基因組分析工作流程並擴展了定序能力；羅氏透過拓展伴隨診斷合作夥伴關係，強化了其精準腫瘤產品組合；賽默飛世爾科技為臨床腫瘤實驗室實施了先進的NGS工作流程解決方案；以及Guardant Health擴展了液態生物檢體的應用，以支持綜合基因組分析。

簡明結論

  • 癌症基因組分析市場預計將持續成長，這主要得益於精準腫瘤學、技術創新以及醫療保健投資的不斷擴大。從單基因檢測到全面基因組分析的轉變，標誌著腫瘤學實踐的根本性變革。儘管高成本、有限的保險報銷以及數據解讀的複雜性等挑戰依然存在，但生物資訊學領域的技術進步、夥伴關係和策略投資正為市場領導提供持續的競爭優勢。長期市場前景依然樂觀，癌症基因組分析正逐步發展成為現代腫瘤學的基石，為全球醫療保健系統的個人化治療選擇、治療監測以及患者預後的改善提供支持。

本報告的主要益處：

  • 深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
  • 競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
  • 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
  • 實用建議：我們支援制定策略決策，以開發新的收入來源。
  • 適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

    產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

  • 歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
  • 競爭對手定位、策略和市場佔有率分析
  • 營收成長率及預測分析：依業務板塊及地區（國家）分類
  • 企業概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章：執行摘要

  • 市場概述
  • 主要分析結果
  • 分析師意見
  • 策略建議

第2章 分析方法

  • 分析設計
  • 資料收集和分析方法
  • 市場規模估算
  • 預測模型
  • 先決條件和限制

第3章：全球癌症基因組分析市場：概述、市場規模與預測

  • 市場定義和範圍
  • 行業概覽
  • 癌症基因組分析概述
  • 主要市場趨勢
  • 實際成果值市場規模分析
  • 市場預測
  • 癌症患者數量分析
  • 對基因組檢測數量的分析
  • 分析腫瘤詳細檢查實施情
  • 臨床工作流程分析

第4章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰

第5章 行業情勢

  • 產業價值鏈分析
  • 定價分析
  • 還款狀態

第6章：創新趨勢

  • 新興技術
  • 產品創新
  • 綜合基因組分析的進展
  • 人工智慧在基因組數據解讀的應用
  • 多體學整合
  • 基於液態生物檢體的基因組分析
  • 技術藍圖

第7章 監理情勢

  • 法律規範
  • 核准流程
  • 合規要求

第8章：全球癌症基因組分析市場：展望分析

  • 分析：按分析類型
    • 全面基因組分析
    • 標靶基因組分析
    • 全EXOME定序（WES）
    • 全基因測序（WGS）
  • 分析：按技術
    • 次世代定序（NGS）
    • 聚合酵素鏈鎖反應（PCR）
    • 螢光原位雜合反應（FISH）
    • 微陣列
    • 桑格定序
  • 分析：依生物標記類型
    • 單核苷酸多態性（SNV）
    • 拷貝數變異（CNV）
    • 基因融合
    • 微衛星不穩定性（MSI）
    • 腫瘤突變負荷（TMB）
  • 分析：透過臨床應用
    • 治療方案
    • 伴隨診斷
    • 預後評估
    • 疾病監測
    • 臨床研究

第9章 全球癌症基因組分析市場：細分市場分析

  • 依產品
    • 裝置
    • 試劑和耗材
    • 軟體、生物資訊學
  • 透過技術
    • 次世代定序（NGS）
    • 聚合酵素鏈鎖反應（PCR）
    • 螢光原位雜合反應（FISH）
    • 微陣列
    • 桑格定序
    • 其他技術
  • 依檢體類型
    • 組織檢體
    • 血液檢體
    • 骨髓檢體
    • 其他類型的檢體
  • 最終用戶
    • 醫院
    • 診斷檢查室
    • 癌症中心
    • 學術研究機構

第10章：全球癌症基因組分析市場：區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第11章 全球癌症基因體分析市場：國別分析

  • 美國
  • 加拿大
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 日本
  • 中國
  • 韓國
  • 印度
  • 澳洲
  • 巴西
  • 墨西哥
  • 沙烏地阿拉伯
  • 南非

第12章 競爭格局

  • 市佔率分析
  • 策略趨勢
  • 企業合併、商業夥伴關係和合作
  • 新產品發布

第13章：公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • Guardant Health, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine, Inc.
  • Tempus AI, Inc.
  • NeoGenomics Laboratories, Inc.
  • Personalis, Inc.
  • Caris Life Sciences
  • Bio-Rad Laboratories, Inc.
  • Abbott Laboratories

第14章 全球癌症基因組分析市場：商業預測分析

第15章 投資與資金籌措分析

  • 創業投資趨勢
  • 政府資金
  • 研發投資

第16章：未來展望

  • 主要成長機遇
  • 未來產業趨勢
簡介目錄
Product Code: KSI-009088

The Cancer Genomic Profiling Market is set to reach USD 23.14 billion in 2035, growing at a CAGR of 11.7 % from USD 8.58 billion in 2026.

The cancer genomic profiling market is undergoing significant transformation driven by the paradigm shift toward precision oncology and the growing recognition that comprehensive molecular characterization is essential for personalized cancer treatment. The market's evolution is characterized by the increasing adoption of next-generation sequencing and multi-omics approaches to identify actionable mutations, guide therapy selection, and monitor disease progression across multiple cancer types. The convergence of advanced sequencing technologies, artificial intelligence, and liquid biopsy platforms is enabling faster, more comprehensive, and increasingly accessible genomic analysis. Healthcare systems worldwide are expanding genomic testing capabilities as targeted therapies and immunotherapies require biomarker-driven patient selection. The market is witnessing significant investment in comprehensive genomic profiling, companion diagnostics, and bioinformatics solutions, positioning cancer genomic profiling as a cornerstone of modern oncology practice.

Market Drivers

  • The growing adoption of precision oncology represents the primary driver for the cancer genomic profiling market. Precision medicine requires comprehensive genomic profiling to identify actionable mutations and personalize cancer treatment strategies. Healthcare providers are expanding genomic testing programs to support targeted therapy selection and improve patient outcomes. Diagnostic manufacturers are developing comprehensive genomic profiling solutions to capture growing demand. This requirement strengthens demand for genomic testing across all cancer types, resulting in sustained growth in cancer genomic profiling utilization. Rapid advancements in next-generation sequencing technologies are further accelerating market growth through improved diagnostic accuracy, throughput, affordability, and accessibility across clinical laboratories worldwide. Continuous innovation in sequencing chemistry, automation, and bioinformatics is expanding the clinical utility of genomic profiling. Technology developers are reducing sequencing costs while improving analytical performance. These advancements support broader clinical adoption and increased testing volumes. Expanding approvals of targeted therapies and companion diagnostics are accelerating routine genomic testing in oncology clinical practice and research. Regulatory approvals for biomarker-driven therapies create sustained demand for companion diagnostic testing. Pharmaceutical companies are expanding targeted therapy pipelines that require genomic characterization for patient selection. Diagnostic manufacturers are developing companion diagnostic solutions to support therapeutic approvals and commercialization. Rising global cancer incidence and increasing biomarker-driven treatment approaches strengthen demand for comprehensive molecular profiling solutions. Growing cancer burden creates sustained demand for diagnostic testing across screening, diagnosis, treatment selection, and monitoring applications. Healthcare systems are expanding genomic testing capacity to support personalized treatment strategies.

Market Restraints

  • High costs of genomic sequencing platforms and bioinformatics infrastructure limit adoption among smaller hospitals and diagnostic laboratories. The significant financial investment required for advanced technologies creates barriers for smaller facilities. Limited reimbursement coverage for comprehensive genomic profiling remains a barrier in several emerging healthcare markets. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Complex genomic data interpretation requires specialized expertise and advanced bioinformatics capabilities, restricting widespread clinical implementation. The shortage of trained personnel and bioinformatics infrastructure limits the scalability of genomic profiling. Variability in regulatory requirements across countries delays commercialization and global adoption of advanced genomic profiling technologies.

Technology and Profiling Type Insights

  • The technology landscape is characterized by the growing importance of comprehensive genomic profiling and integrated bioinformatics platforms. NGS dominates the technology landscape because of its ability to simultaneously analyze multiple genomic alterations with high sensitivity and throughput. PCR remains widely utilized for targeted mutation detection and companion diagnostics. FISH continues serving an important role in chromosomal abnormality analysis. Microarray technology supports gene expression profiling. Sanger sequencing remains valuable for confirmatory testing and validation. The segment analysis reveals that comprehensive genomic profiling is the fastest-growing profiling type due to increasing demand for broad molecular characterization to guide treatment decisions. Targeted gene panel profiling remains important for focused analysis of clinically actionable genes. WES and WGS are expanding for research and specific clinical applications where comprehensive genomic information is required. Tissue samples remain the gold standard for comprehensive genomic profiling due to their ability to provide high-quality DNA and complete tumor characterization. Blood samples are witnessing the fastest growth as liquid biopsy technologies enable minimally invasive genomic testing, treatment monitoring, and recurrence detection. Therapy selection represents the primary clinical application, with companion diagnostics and prognostic assessment experiencing rapid growth. Hospitals and diagnostic laboratories represent the leading end-user segments, with cancer centers and academic research institutes expanding genomic testing capabilities. The integration of AI is becoming increasingly important as AI-powered bioinformatics enhances genomic data interpretation, clinical decision support, and precision oncology workflow efficiency.

Competitive and Strategic Outlook

  • The competitive landscape features established diagnostics and life science companies alongside specialized genomic testing, bioinformatics, and liquid biopsy providers. Roche develops comprehensive molecular diagnostics, companion diagnostics, sequencing technologies, and precision oncology solutions supporting genomic profiling. Illumina is a global leader in NGS platforms enabling comprehensive cancer genomic profiling and precision medicine. Thermo Fisher Scientific provides sequencing systems, PCR technologies, genomic analysis solutions, and oncology research platforms. QIAGEN develops molecular diagnostics, sample preparation technologies, PCR assays, and bioinformatics solutions supporting genomic testing. Agilent delivers genomics instrumentation, molecular assays, automation technologies, and bioinformatics solutions for oncology diagnostics. Danaher provides advanced genomics platforms, molecular diagnostic technologies, sequencing solutions, and laboratory automation systems. Guardant Health specializes in liquid biopsy, comprehensive genomic profiling, and precision oncology testing for advanced cancer management. Exact Sciences develops molecular cancer diagnostics, genomic profiling technologies, and precision oncology testing solutions. Foundation Medicine specializes in comprehensive genomic profiling, companion diagnostics, and precision oncology testing. Companies are pursuing product portfolio expansion through innovation in NGS platforms, liquid biopsy assays, and AI-enabled bioinformatics. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision oncology solutions. Recent key developments include Illumina expanding oncology sequencing capabilities with enhanced comprehensive genomic profiling workflows. Roche strengthened its precision oncology portfolio through expanded companion diagnostic collaborations. Thermo Fisher Scientific introduced advanced NGS workflow solutions for clinical oncology laboratories. Guardant Health expanded liquid biopsy applications supporting comprehensive genomic profiling.

Short Conclusion

  • The cancer genomic profiling market is positioned for sustained growth driven by the convergence of precision oncology, technological innovation, and expanding healthcare investment. The transition from single-gene testing toward comprehensive genomic profiling represents a fundamental shift in oncology practice. While challenges related to high costs, reimbursement limitations, and data interpretation complexity persist, strategic investments in technology, partnerships, and bioinformatics are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with cancer genomic profiling evolving into a cornerstone of modern oncology, supporting personalized treatment selection, therapy monitoring, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Findings
  • 1.3 Analyst Insights
  • 1.4 Strategic Recommendations

2. Research Methodology

  • 2.1 Research Design
  • 2.2 Data Collection Methodology
  • 2.3 Market Size Estimation
  • 2.4 Forecasting Model
  • 2.5 Assumptions & Limitations

3. Global Cancer Genomic Profiling Market Overview, Size & Forecast

  • 3.1 Market Definition & Scope
  • 3.2 Industry Overview
  • 3.3 Evolution of Cancer Genomic Profiling
  • 3.4 Key Market Trends
  • 3.5 Historical Market Size Analysis (2021-2025)
  • 3.6 Market Forecast (2026-2035)
  • 3.7 Cancer Patient Population Analysis
  • 3.8 Genomic Testing Volume Analysis
  • 3.9 Precision Oncology Adoption Analysis
  • 3.10 Clinical Workflow Analysis

4. Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Market Restraints
  • 4.3 Market Opportunities
  • 4.4 Market Challenges

5. Industry Landscape

  • 5.1 Industry Value Chain Analysis
  • 5.2 Pricing Analysis
  • 5.3 Reimbursement Landscape

6. Innovation Landscape

  • 6.1 Emerging Technologies
  • 6.2 Product Innovation
  • 6.3 Comprehensive Genomic Profiling Advancements
  • 6.4 Artificial Intelligence in Genomic Data Interpretation
  • 6.5 Multi-Omics Integration
  • 6.6 Liquid Biopsy-Based Genomic Profiling
  • 6.7 Technology Roadmap

7. Regulatory Landscape

  • 7.1 Regulatory Framework
  • 7.2 Approval Pathways
  • 7.3 Compliance Requirements

8. Global Cancer Genomic Profiling Market Landscape Analysis

  • 8.1 Analysis by Profiling Type
    • 8.1.1 Comprehensive Genomic Profiling
    • 8.1.2 Targeted Gene Panel Profiling
    • 8.1.3 Whole Exome Sequencing (WES)
    • 8.1.4 Whole Genome Sequencing (WGS)
  • 8.2 Analysis by Technology
    • 8.2.1 Next-Generation Sequencing (NGS)
    • 8.2.2 Polymerase Chain Reaction (PCR)
    • 8.2.3 Fluorescence In Situ Hybridization (FISH)
    • 8.2.4 Microarray
    • 8.2.5 Sanger Sequencing
  • 8.3 Analysis by Biomarker Type
    • 8.3.1 Single Nucleotide Variants (SNVs)
    • 8.3.2 Copy Number Variations (CNVs)
    • 8.3.3 Gene Fusions
    • 8.3.4 Microsatellite Instability (MSI)
    • 8.3.5 Tumor Mutational Burden (TMB)
  • 8.4 Analysis by Clinical Application
    • 8.4.1 Therapy Selection
    • 8.4.2 Companion Diagnostics
    • 8.4.3 Prognostic Assessment
    • 8.4.4 Disease Monitoring
    • 8.4.5 Clinical Research

9. Global Cancer Genomic Profiling Market Segment Analysis (2021-2035)

  • 9.1 By Product
    • 9.1.1 Instruments
    • 9.1.2 Reagents & Consumables
    • 9.1.3 Software & Bioinformatics
  • 9.2 By Technology
    • 9.2.1 Next-Generation Sequencing (NGS)
    • 9.2.2 Polymerase Chain Reaction (PCR)
    • 9.2.3 Fluorescence In Situ Hybridization (FISH)
    • 9.2.4 Microarray
    • 9.2.5 Sanger Sequencing
    • 9.2.6 Other Technologies
  • 9.3 By Sample Type
    • 9.3.1 Tissue Samples
    • 9.3.2 Blood Samples
    • 9.3.3 Bone Marrow Samples
    • 9.3.4 Other Sample Types
  • 9.4 By End User
    • 9.4.1 Hospitals
    • 9.4.2 Diagnostic Laboratories
    • 9.4.3 Cancer Centers
    • 9.4.4 Academic & Research Institutes

10. Global Cancer Genomic Profiling Market Geographical Analysis (2021-2035)

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 South America
  • 10.5 Middle East & Africa

11. Global Cancer Genomic Profiling Market Country Analysis (2021-2035)

  • 11.1 United States
  • 11.2 Canada
  • 11.3 Germany
  • 11.4 United Kingdom
  • 11.5 France
  • 11.6 Italy
  • 11.7 Spain
  • 11.8 Japan
  • 11.9 China
  • 11.10 South Korea
  • 11.11 India
  • 11.12 Australia
  • 11.13 Brazil
  • 11.14 Mexico
  • 11.15 Saudi Arabia
  • 11.16 South Africa

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Strategic Developments
  • 12.3 Mergers & Acquisitions, Partnerships & Collaborations
  • 12.4 Product Launches

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd.
    • 13.1.1 Company Overview
    • 13.1.2 Financials
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Developments
  • 13.2 Illumina, Inc.
    • 13.2.1 Company Overview
    • 13.2.2 Financials
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Developments
  • 13.3 Thermo Fisher Scientific Inc.
    • 13.3.1 Company Overview
    • 13.3.2 Financials
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Developments
  • 13.4 QIAGEN N.V.
    • 13.4.1 Company Overview
    • 13.4.2 Financials
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Developments
  • 13.5 Agilent Technologies, Inc.
    • 13.5.1 Company Overview
    • 13.5.2 Financials
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Developments
  • 13.6 Danaher Corporation
    • 13.6.1 Company Overview
    • 13.6.2 Financials
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Developments
  • 13.7 Guardant Health, Inc.
    • 13.7.1 Company Overview
    • 13.7.2 Financials
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Developments
  • 13.8 Exact Sciences Corporation
    • 13.8.1 Company Overview
    • 13.8.2 Financials
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Developments
  • 13.9 Foundation Medicine, Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Financials
    • 13.9.3 Product Portfolio
    • 13.9.4 Recent Developments
  • 13.10 Tempus AI, Inc.
    • 13.10.1 Company Overview
    • 13.10.2 Financials
    • 13.10.3 Product Portfolio
    • 13.10.4 Recent Developments
  • 13.11 NeoGenomics Laboratories, Inc.
    • 13.11.1 Company Overview
    • 13.11.2 Financials
    • 13.11.3 Product Portfolio
    • 13.11.4 Recent Developments
  • 13.12 Personalis, Inc.
    • 13.12.1 Company Overview
    • 13.12.2 Financials
    • 13.12.3 Product Portfolio
    • 13.12.4 Recent Developments
  • 13.13 Caris Life Sciences
    • 13.13.1 Company Overview
    • 13.13.2 Financials
    • 13.13.3 Product Portfolio
    • 13.13.4 Recent Developments
  • 13.14 Bio-Rad Laboratories, Inc.
    • 13.14.1 Company Overview
    • 13.14.2 Financials
    • 13.14.3 Product Portfolio
    • 13.14.4 Recent Developments
  • 13.15 Abbott Laboratories
    • 13.15.1 Company Overview
    • 13.15.2 Financials
    • 13.15.3 Product Portfolio
    • 13.15.4 Recent Developments

14. Global Cancer Genomic Profiling Market Commercial Forecast Analysis

  • 14.1 Comprehensive Genomic Profiling (CGP) Tests
  • 14.2 Targeted Gene Panel Tests
  • 14.3 Whole Exome Sequencing (WES)
  • 14.4 Whole Genome Sequencing (WGS)
  • 14.5 Liquid Biopsy-Based Genomic Profiling
  • 14.6 Companion Diagnostic Genomic Tests
  • 14.7 Bioinformatics and Genomic Interpretation Solutions

15. Investment & Funding Analysis

  • 15.1 Venture Capital Trends
  • 15.2 Government Funding
  • 15.3 R&D Investments

16. Future Outlook

  • 16.1 Key Growth Opportunities
  • 16.2 Future Industry Trends